{"id":6125,"date":"2019-10-08T10:31:12","date_gmt":"2019-10-08T05:01:12","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=6125"},"modified":"2021-07-24T12:57:35","modified_gmt":"2021-07-24T07:27:35","slug":"pharma-happenings-for-angiodynamics-eximo-mirobio-janssen","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-angiodynamics-eximo-mirobio-janssen","title":{"rendered":"AngioDynamics acquires Eximo; MiroBio raises USD 33 M; Janssen submits sBLA for Stelara"},"content":{"rendered":"\n<h4 class=\"wp-block-heading\"><strong>AngioDynamics, an innovative\nmedical devices provider, has signed an upfront USD 46 Million deal to acquire Eximo\nMedical. <\/strong><\/h4>\n\n\n\n<p>AngioDynamics is a leading player\nin manufacturing medical devices for vascular access, peripheral vascular\ndisease, and oncology. The acquisition of Eximo Medical will increase the\nportfolio of AngioDynamics by adding Eximo\u2019s proprietary 355nm wavelength laser\ntechnology, which has received 510(k) clearance for use in the Peripheral\nArtery Disease (PAD) treatment.<\/p>\n\n\n\n<p>The survey released by the companies revealed that over 2,00,000 Americans suffering from PAD receiving atherectomy treatment get benefitted from Eximo\u2019s laser technology. With the deal, AngioDynamics is all set to enter into a versatile USD 500 Million markets of innovating and latest medical devices. <\/p>\n\n\n\n<p>Approximately 8.5 million people\nin the United States have PAD, including 12-20% of individuals older than age\n60, according to CDC. <\/p>\n\n\n\n<p>The deal is done all through cash\non hand with up to USD 20 Million of contingency payments on achieving\ntechnical and revenue related milestones totalling the deal to USD 66 Million. <\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>MiroBio, UK-based therapeutics, has raised USD 33 Million in the first round of financing to fuel its pipeline for autoimmune and inflammatory disorders.<\/strong><\/h4>\n\n\n\n<p>The funds will be used to support\nresearch into immune cell regulation and develop antibodies to treat autoimmune\ndiseases by stimulating specific immune cell signals. It will help the company\nto expand its horizon in an approach it is working to treat autoimmune diseases,\ni.e., antibody modulators of immune cell receptors, an approach that has\npotential across a range of diseases, with an initial focus on auto-immune\ndisease.<\/p>\n\n\n\n<p>The financing round was co-led by\nOxford Sciences Innovation and Samsara Biocapital along with life science\ninvestors Advent Life Sciences and SR One.<\/p>\n\n\n\n<p>At present, 50 million Americans are\nliving with a type of Autoimmune Disease. As per records of NIH, the organization\nhas spent USD 591 million dollars on Autoimmune Disease research compared to\nthe USD 6.1 billion spent on cancer.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>Janssen Pharmaceuticals has submitted a supplemental Biologics License Application (sBLA) to the FDA for the approval of its STELARA (ustekinumab) to treat moderate to severe plaque psoriasis in the paediatric population. <\/strong><\/h4>\n\n\n\n<p>Sterlara is the only biologic drug which targets and blocks both the cytokines interleukin (IL)-12 and IL-23. These cytokine interleukins play a significant role in inflammation-related with auto-immune conditions, such as PsO. <\/p>\n\n\n\n<p>Currently, the drug is approved\nfor the treatment of adolescents and adults living with moderate to severe\nplaque psoriasis (ages 12+), adults with active psoriatic arthritis, adults\nwith moderate to severe Crohn&#8217;s disease and adults with moderate to severe\nulcerative colitis in the EU and other countries.<\/p>\n\n\n\n<p>According to the National Psoriasis Foundation (NPF), more than 8 million Americans have psoriasis. Plaque psoriasis is the most common form of the disease, affecting 80 per cent of those with psoriasis.<\/p>\n\n\n\n<p>Major players such as\nBristol-Myers Squibb, Dermavant Sciences GmbH, Arcutis, Inc., Avillion LLP are involved\nin developing therapies for the treatment and management of Plaque Psoriasis.\nThese therapies are currently under different stages of development. <\/p>\n","protected":false},"excerpt":{"rendered":"<p>AngioDynamics, an innovative medical devices provider, has signed an upfront USD 46 Million deal to acquire Eximo Medical. AngioDynamics is a leading player in manufacturing medical devices for vascular access, peripheral vascular disease, and oncology. The acquisition of Eximo Medical will increase the portfolio of AngioDynamics by adding Eximo\u2019s proprietary 355nm wavelength laser technology, which [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":5118,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[1271,639,5789],"industry":[17226,17225],"therapeutic_areas":[17237,17227],"class_list":["post-6125","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-delveinsight-pharma-news","tag-pharma-news","tag-recent-pharma-news","industry-medical-devices","industry-pharmaceutical","therapeutic_areas-dermatology","therapeutic_areas-immunological-and-autoimmune-disorders"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>AngioDynamics acquires Eximo; MiroBio raises USD 33 Million<\/title>\n<meta name=\"description\" content=\"Janssen Pharmaceuticals has submitted a sBLA to the FDA for the approval of its STELARA (ustekinumab) to treat moderate to severe plaque psoriasis...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-angiodynamics-eximo-mirobio-janssen\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AngioDynamics acquires Eximo; MiroBio raises USD 33 Million\" \/>\n<meta property=\"og:description\" content=\"Janssen Pharmaceuticals has submitted a sBLA to the FDA for the approval of its STELARA (ustekinumab) to treat moderate to severe plaque psoriasis...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-angiodynamics-eximo-mirobio-janssen\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2019-10-08T05:01:12+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:27:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/05\/09021239\/Business-23-may.png\" \/>\n\t<meta property=\"og:image:width\" content=\"647\" \/>\n\t<meta property=\"og:image:height\" content=\"345\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"AngioDynamics acquires Eximo; MiroBio raises USD 33 Million","description":"Janssen Pharmaceuticals has submitted a sBLA to the FDA for the approval of its STELARA (ustekinumab) to treat moderate to severe plaque psoriasis...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-angiodynamics-eximo-mirobio-janssen","og_locale":"en_US","og_type":"article","og_title":"AngioDynamics acquires Eximo; MiroBio raises USD 33 Million","og_description":"Janssen Pharmaceuticals has submitted a sBLA to the FDA for the approval of its STELARA (ustekinumab) to treat moderate to severe plaque psoriasis...","og_url":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-angiodynamics-eximo-mirobio-janssen","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2019-10-08T05:01:12+00:00","article_modified_time":"2021-07-24T07:27:35+00:00","og_image":[{"width":647,"height":345,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/05\/09021239\/Business-23-may.png","type":"image\/png"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-angiodynamics-eximo-mirobio-janssen","url":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-angiodynamics-eximo-mirobio-janssen","name":"AngioDynamics acquires Eximo; MiroBio raises USD 33 Million","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-angiodynamics-eximo-mirobio-janssen#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-angiodynamics-eximo-mirobio-janssen#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/05\/09021239\/Business-23-may.png","datePublished":"2019-10-08T05:01:12+00:00","dateModified":"2021-07-24T07:27:35+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Janssen Pharmaceuticals has submitted a sBLA to the FDA for the approval of its STELARA (ustekinumab) to treat moderate to severe plaque psoriasis...","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-angiodynamics-eximo-mirobio-janssen"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-angiodynamics-eximo-mirobio-janssen#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/05\/09021239\/Business-23-may.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/05\/09021239\/Business-23-may.png","width":647,"height":345,"caption":"Business cocktail"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/05\/09021239\/Business-23-may-300x160.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">delveinsight pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">recent pharma news<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">delveinsight pharma news<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>","<span class=\"advgb-post-tax-term\">recent pharma news<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 7 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Oct 8, 2019","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Oct 8, 2019 10:31 am","modified":"Updated on Jul 24, 2021 12:57 pm"},"featured_img_caption":"Business cocktail","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/6125","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=6125"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/6125\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/5118"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=6125"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=6125"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=6125"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=6125"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=6125"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}